Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8771582 | The Journal of Urology | 2018 | 9 Pages |
Abstract
After a complete response to trimodality therapy nonmuscle invasive bladder cancer recurred in 25% of patients, developing in some of them more than a decade after trimodality therapy. No baseline clinicopathological characteristics were associated with such recurrence after a complete response. Patients with nonmuscle invasive bladder cancer recurrence had worse disease specific survival than those without such recurrence but similar overall survival. Adjuvant intravesical bacillus Calmette-Guérin had a reasonable toxicity profile and efficacy in this population. Properly selected patients with recurrent nonmuscle invasive bladder cancer after a complete response may avoid immediate salvage cystectomy.
Keywords
DSSnonMIBCMIBCNMIBCTURBTTMTCISRFSBCGSRCBacillus Calmette-GuérinPFsprogression-free survivalDisease specific survivalRecurrence-free survivaloverall survivalNeoplasm invasivenessTrimodality therapytransurethral bladder tumor resectionMuscle invasive bladder cancerUrinary bladder neoplasmsRadical cystectomyNeoplasm recurrenceLocalMortalityBCG vaccinecomplete responseCarcinoma in situ
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Alejandro Sanchez, Matthew F. Wszolek, Andrzej Niemierko, Rebecca H. Clayman, Michael Drumm, Dayron RodrÃguez, Adam S. Feldman, Douglas M. Dahl, Niall M. Heney, William U. Shipley, Anthony L. Zietman, Jason A. Efstathiou,